What are opportunistic infections?
People with advanced HIV infection are vulnerable to infections and
malignancies that are called 'opportunistic infections' because they
take advantage of the opportunity offered by a weakened immune system.
A partial list of the world's most common HIV-related opportunistic
infections and diseases includes:
- Bacterial diseases such as tuberculosis, MAC, bacterial pneumonia and
septicaemia (blood poisoning)
- Protozoal diseases such as toxoplasmosis, microsporidiosis,
cryptosporidiosis, isopsoriasis and leishmaniasis
- Fungal diseases such as PCP, candidiasis, cryptococcosis and
penicilliosis
- Viral diseases such as those caused by cytomegalovirus, herpes
simplex and herpes zoster virus
- HIV-associated malignancies such as Kaposi's sarcoma, lymphoma and
squamous cell carcinoma.
Different conditions typically occur at different
stages of HIV infection. In early HIV
disease people can develop tuberculosis, malaria, bacterial pneumonia,
herpes zoster, staphylococcal skin infections and septicaemia. These
are diseases that people with normal immune systems can also get, but
with HIV they occur at a much higher rate. It also takes longer for a
person with HIV to recover than it takes for someone with a healthy
immune system.
When the immune system is very weak due to advanced HIV disease or
AIDS, opportunistic infections such as PCP, toxoplasmosis and
cryptococcosis develop. Some infections can spread to a number of
different organs, which is known as 'disseminated' or 'systemic'
disease. Many of the opportunistic infections that occur at this late
stage can be fatal.
Why is there still a need to prevent and treat
opportunistic infections?
Highly Active Antiretroviral Therapy
(HAART) can reduce the amount of HIV in someone's body and restore
their immune system. The introduction of HAART has dramatically reduced
the incidence of opportunistic infections among HIV-positive people who
have received the drugs. Yet the prevention and treatment of
opportunistic infections remains essential.
Around the world, millions of people living with HIV in resource-poor
communities have no access to antiretroviral drugs. And even where the
drugs are available, they do not entirely remove the need for
preventing and treating opportunistic infections. Usually it is
advisable for people with acute opportunistic infections to begin HIV
treatment right away, especially if the infection is difficult to
treat. However in certain cases it may be better to delay beginning HIV
treatment and instead only to administer treatment for the
opportunistic infection, especially if there are concerns about drug
interactions or overlapping drug toxicities.
Those who have already started taking antiretrovirals may require other
drugs in certain circumstances. In particular, some opportunistic
infections may be unmasked shortly after starting HIV treatment as the
immune system starts to recover, and these may require specific
treatment. Measures to prevent and treat opportunistic infections
become essential if antiretrovirals stop working because of poor
adherence, drug resistance or other factors.
Providing prevention and treatment of opportunistic infections not only
helps HIV-positive people to live longer, healthier lives, but can also
help prevent TB and other transmissible opportunistic infections from
spreading to others.
Prevention of HIV-related opportunistic
infections
HIV-positive people can reduce their exposure to some of the germs that
threaten their health. They should be especially careful around
uncooked meat, domestic animals, human excrement and lake or river
water. However there is no practical way to reduce exposure to the
germs that cause candidiasis, MAC, bacterial pneumonia and other
diseases because they are generally common in the environment.
Co-trimoxazole
Several HIV-related infections (including tuberculosis, bacterial
pneumonia, malaria, septicaemia and PCP) can be prevented using drugs.
This is known as drug prophylaxis. One particular drug called
co-trimoxazole (also known as septra, bactrim and TMP-SMX) is effective
at preventing a number of opportunistic infections and has been shown
to significantly reduce mortality among HIV-positive individuals
initiating antiretroviral therapy.
1 Although the drug
is both cheap and widely available, many countries have still failed to
implement policies to provide nationwide coverage of the
drug.
The World Health Organisation (WHO) recommends that, in
resource-limited settings, the following groups of people should begin
taking co-trimoxazole:
- HIV-exposed infants and children, starting at 4-6 weeks after
birth, or at first contact with health care, and continued until HIV
infection is excluded
- HIV-positive children less than 1 year old
- HIV-positive children aged 1-4 years who have mild, advanced or
severe symptoms of HIV disease, or a CD4 count below 25%
- HIV-positive adults and adolescents who have mild, advanced or
severe symptoms of HIV disease, or a CD4 count below 350 cells per ml
- HIV-positive people with a history of treated PCP.
According to WHO guidelines, treatment of HIV-positive children should
continue until at least age five. In general treatment of adults and
children should continue indefinitely, though it may sometimes be
stopped following successful antiretroviral treatment.
Some of the worst affected countries may choose to treat all infants
and children born to mothers confirmed or suspected of living with HIV,
until HIV infection is excluded. They may also choose to treat everyone
who is diagnosed with HIV, regardless of symptoms or CD4 count.
Drug prophylaxis is sometimes recommended even for those who have
started ART if they have very weak immune systems or are otherwise
considered to be especially vulnerable. They may be advised to stop
taking the drugs if their immune system recovers.
For people who have already contracted an opportunistic infection and
undergone successful treatment, secondary prophylaxis may be advisable
to prevent recurrence. This applies to diseases such as tuberculosis,
salmonella, cryptococcosis and PCP.
Treatment of HIV-related opportunistic
infections
Some opportunistic infections are easier to treat than others.
Effective treatment depends on health services being able to procure,
store, select and administer the necessary drugs and to provide related
treatment, care and diagnostic services to monitor health status and
treatment response.
A few opportunistic infections and symptoms such as candidiasis of the
mouth, throat or vagina (thrush), herpes zoster (shingles) and herpes
simplex can be managed effectively through
home based care. In a
home-based care setting diagnosis is made by observing symptoms.
Some opportunistic infections may be diagnosed by observation or using
a microscope, and treated where there is minimal health infrastructure.
Such infections include pulmonary tuberculosis and cryptococcal
meningitis.
In a medium infrastructure setting, the facilities available include
X-ray equipment and culture facilities. Using these, opportunistic
infections such as extra-pulmonary tuberculosis, cryptosporidiosis,
isopsoriasis, PCP and Kaposi's sarcoma can be diagnosed and treated.
Opportunistic infections such as toxoplasmosis, MAC and cytomegalovirus
infection can be diagnosed and treated in places with advanced
infrastructure. Treating these infections is often impossible in
resource poor countries. Many developing countries lack the advanced
equipment and infrastructure (such as CT scanning) needed to treat
these more complex infections.
See our page on
AIDS and
pain for information on treating pain associated with opportunistic
infections.
Individual opportunistic infections
The following are just a few of the conditions that particularly affect
people living with HIV.
Bacterial pneumonia
Pneumonia can be caused by various bacteria. Symptoms among
HIV-positive people are much the same as in those without HIV
infection, and include chills, rigours, chest pain and pus in the
sputum. The vaccine PPV can protect people against some of the more
common pneumonia-causing bacteria, and is recommended in the US.
Because other forms of respiratory infection, including PCP, are common
among HIV-infected people, doctors must be certain of diagnosis before
administering antibiotics. This may require a chest radiograph, blood
cultures, a white blood cell count and tests to eliminate other
infections. Treatment is usually aimed at the most commonly identified
disease-causing bacteria.
Candidiasis
There are two main types of candidiasis: localised disease (of the
mouth and throat or of the vagina) and systemic disease (of the
oesophagus, and disseminated disease). HIV-positive women commonly
acquire the mouth and throat variant (usually known as thrush or OPC).
It is believed to occur at least once in the lifetime of all
HIV-infected patients. OPC in HIV-positive patients indicates a decline
in immunodeficiency and, when ART is absent, is a sign of the onset of
AIDS. However, the vaginal variant is a common occurrence among
HIV-negative women.
While OPC is not a cause of death, it causes severe discomfort. The
symptoms of candidiasis of the vagina include itching and possibly a
thick vaginal discharge. Candidiasis of the mouth and throat can cause
oral pain and make swallowing difficult, the main symptom is creamy
white legions in the mouth that can be scraped away. Oesophageal
(gullet) candidiasis is a more serious condition which can cause pain
in the chest that increases with swallowing. Disseminated candidiasis
causes fever and symptoms in the organs affected by the disease (for
example, blindness when it affects the eyes), and can be life
threatening.
Localised disease may be treated at first with relatively inexpensive
drugs such as nystatin, miconazole or clotrimazole. Systemic
candidiasis requires treatment with systemic antifungal agents such as
fluconazole, ketoconazole, itraconazole or amphotericin.
Cryptococcosis
Cryptococcosis is caused by a fungus that primarily infects the brain.
It most often appears as meningitis and occasionally as pulmonary or
disseminated disease. Untreated cryptococcal meningitis is fatal.
Cryptococcosis is relatively easy to diagnose. However, its treatment
(either amphotericin B with or without flucytosine or in mild cases
with oral fluconazole) and secondary chemoprophylaxis are often
impossible in developing countries because of high cost and limited
availability of the drugs required.
It is recommended that ART should be administered to those diagnosed
with cryptococcal disease. In the case of cryptococcal meningitis there
are risks of initiating ART as there is evidence that immune
reconstitution inflammatory syndrome (IRIS) may develop. HIV
progression versus the onset of IRIS are risks that must be weighed
when treating HIV and cryptococcosis meningitis.
Cryptosporidiosis and isosporiasis
Cryptosporidiosis (crypto) and isosporiasis are both caused by
protozoan parasites. These diseases are easily spread by contaminated
food or water, or by direct contact with an infected person or animal.
Both crypto and isosporiasis cause diarrhoea, nausea, vomiting and
stomach cramps. In people with healthy immune systems, these symptoms
do not last more than about 14 days. However, if the immune system is
damaged then they can continue for a long time. Diarrhoea can interfere
with the absorption of nutrients and this can lead to serious weight
loss.
To confirm diagnosis of either disease, the stool is normally checked
for parasites and their eggs. There is no cure for crypto, but
antiretroviral therapy to restore immunity can effectively clear up the
infection. For isosporiasis, TMP-SMX (trimethoprim-sulfamethoxazole) is
often the preferred treatment.
Cytomegalovirus
Cytomegalovirus (CMV) is a virus that infects the whole body. Infection
usually occurs in childhood yet the virus remains dormant unless the
immune system is suppressed. It most commonly appears as retinitis,
which causes blurred vision and can lead to blindness, and also as
gastrointestinal disease. CMV can also affect other organs such as the
lungs or liver, and is capable of causing fever, diarrhoea, nausea,
pneumonia-like symptoms and dementia.
CMV infection may be treated with drugs such as ganciclovir,
valganciclovir, cidofovir and forscarnet. Before the roll out of ARV,
studies identified that up to 40% of AIDS patients aquired CMV. Access
to ARV’s now deter the chances of infection as immune systems can
be supported. It is recommended to initiate ART following anti-CMV
treatment in order to reduce the chance of a relapse.
Herpes simplex and Herpes zoster
The usual symptoms of
herpes simplex virus
infection (HSV, which causes sores around the mouth and genitals)
and herpes zoster virus infection (or varicella zoster virus (VZV),
which causes chickenpox (varicella) and shingles (zoster)) are not
life-threatening but can be extremely painful. Both viruses are also
capable of causing retinitis and, less often, encephalitis (which can
be life-threatening). Herpes Zoster is transmitted usually through the
respiratory route, whereas Herpes Simplex Virus is transmitted through
contact with secretions from an infected area.
Both herpes simplex and herpes zoster are usually diagnosed by simple
examination of the affected area, and may be treated with drugs such as
acyclovir, famciclovir and valacyclovir. One particular study found
using acyclovir to treat herpes simplex in those living with HIV and
not taking ARVs, modestly reduces the risk of HIV disease
progression.
3
Histoplasmosis
Histoplasmosis is a fungal infection that primarily affects the lungs
but may also affect other organs. Infection occurs through inhalation
of fungus spores. Symptoms can include fever, fatigue, weight loss and
difficulty in breathing.
Disseminated histoplasmosis infection may be diagnosed using an antigen
test, and can be fatal if left untreated. Treatment usually involves
amphotericin B or itraconazole.
Kaposi's sarcoma
HIV-associated Kaposi's sarcoma causes dark blue lesions, which can
occur in a variety of locations including the skin, mucous membranes,
gastrointestinal tract, lungs or lymph nodes. The lesions usually
appear early in the course of HIV infection.
Treatment depends on the lesions' symptoms and location. For local
lesions, injection therapy with vinblastine has been used with some
success. Radiotherapy can also be used, especially in hard-to reach
sites such as the inner mouth, eyes, face and soles of the feet. For
severe widespread disease, systemic chemotherapy is the preferred
treatment.
Leishmaniasis
Leishmaniasis is transmitted by sandflies and possibly through sharing
needles. The most serious of its four forms is visceral leishmaniasis
(also know as kala azar) which is characterised by irregular bouts of
fever, substantial weight loss, swelling of the spleen and liver and
anaemia (occasionaly serious). In its more common forms, leishmaniasis
can produce disfiguring lesions around the nose, mouth and throat, or
skin ulcers leading to permanent scarring.
Treatment of leishmaniasis is with either a pentavalent antimony or
liposomal amphotericin B in the case of visceral leishmaniasis. Sodium
stibogluconate is used to treat cutaneous leishmaniasis. If left
untreated, visceral leishmaniasis is usually fatal.
MAC
The germs of the mycobacterium avium complex (MAC) are related to the
germ that causes tuberculosis. MAC disease generally affects multiple
organs, and symptoms include fever, night sweats, weight loss, fatigue,
diarrhoea and abdominal pain. It is not believed that person-to-person
transmission occurs; the MAC organisms are present throughout the
environment. Infection occurs through the respiratory or
gastrointestinal tract, infecting individuals with severely inhibited
immune systems.
MAC should be treated using at least two antimycobacterial drugs to
prevent or delay the emergence of resistance. Such drugs include
clarithromycin, azithromycin, ethambutol and rifabutin.
PCP
PCP is caused by a fungus, which was formerly called pneumocystis
carinii but has now been renamed pneumocystis jirovecii. PCP is a
frequent HIV associated opportunistic infection which occurred in
70%-80% of patients with AIDS prior to the widespread use of primary
PCP prophylaxis and ART, which has led to a significant decline of
cases. The symptoms are mainly pneumonia along with fever and
respiratory symptoms such as dry cough, chest pain and dyspnoea
(difficulty in breathing). Definitive diagnosis requires microscopy of
bodily tissues or fluids.
Severe cases of PCP are initially treated with TMP-SMX or clindamycin
and oral primaquine. Mild cases can be treated with oral TMP-SMX
throughout. With both of these regimens, toxicity (notably
allergic-type reactions) often requires changes in therapy.
Prevention of PCP is strongly recommended for HIV-infected persons with
very weak immune systems wherever PCP is a significant health problem
for HIV-infected persons, and also after their first episode of PCP.
The preferred drug is usually TMP-SMX.
Toxoplasmosis
Toxoplasmosis (toxo) is caused by a protozoan found in uncooked meat
and cat faeces. This microbe infects the brain and can cause raised
intracranial pressure, which leads to headaches and vomiting. Other
symptoms include confusion, motor weakness and fever. In the absence of
treatment, disease progression results in seizures, stupour and coma.
Disseminated toxo is less common, but can affect the eyes and cause
pneumonia.
Definitive diagnosis of toxo requires radiographic testing (usually an
MRI scan). The infection is treated with drugs such as pyrimethamine,
sulfadiazine and clindamycin. Leucovorin may also be used to prevent
the side-effects of pyrimethamine. Prophylaxis against toxo is through
taking TMP-SMX.
Recommendations
4 advise
HIV-positive individuals to:
- Avoid ingestion of undercooked meat
- To wash hands after any contact with soil
- To avoid emptying cat litter trays, or to empty trays daily and
wash hands thoroughly after every disposal.
Tuberculosis
Tuberculosis (TB) is a bacterial infection that primarily infects the
lungs. Tuberculosis is the leading HIV-associated opportunistic disease
in developing countries. For people who are dually infected with
HIV and TB, the risk
of developing active tuberculosis is 30-50 fold higher than for people
infected with TB alone. And because mycobacterium can spread through
the air, the increase in active TB cases among dually infected people
means:
- more transmission of the TB germ
- more TB carriers
- more TB in the whole population.
Tuberculosis is harder to diagnose in HIV-positive people than in those
who are uninfected. The diagnosis of TB is important because TB
progresses faster in HIV-infected people. Also, TB in HIV-positive
people is more likely to be fatal if undiagnosed or left untreated. TB
occurs earlier in the course of HIV infection than many other
opportunistic infections.
A proper combination of anti-TB drugs achieves both prevention and
cure. Effective treatment quickly makes the individual non-contagious,
which prevents further spread of the TB germ. The DOTS (directly
observed short course) treatment strategy recommended by WHO treats TB
in HIV-infected persons as effectively as it treats those without the
virus. A complete cure takes 6 to 8 months and uses a combination of
antibiotics. In addition to curing the individual, it also prevents
further spread of the disease to others. This is why treating
infectious cases of TB has important benefits for society as a whole.
Isoniazid preventive therapy is recommended as a health-preserving
measure for HIV-infected persons at risk of TB, as well as for those
with latent TB infection.